Tesla, Gilead Shares Not Pricey Considering Long Term Outlooks

Tesla may currently trade at a high multiple to both earnings and sales, but the revolutionary electric car-maker will grow into its rich valuation, said Ross Gerber, CEO of Gerber Kawasaki. Gerber is similarly bullish about Gilead's future, saying fears about lower emerging market pricing for its hepatitis drug are overblown. He added that Gilead's valuation is cheap relative to earnings considering the biotech giant’s pipeline and powerful R&D division. Finally, Gerber said he remains positive on Apple's stock because he believes the iPhone 6 will be successful. He said Apple will also reap huge profits from its forthcoming mobile payment solution and big screen iPad.